Abstract:

Endometrial carcinoma is a malignant tumor with significant molecular and histological heterogeneity. Different pathological types have different biological behaviors and histological characteristics. Similar to advanced cancers of other histological subtypes, adjuvant radiation therapy is usually used for early-stage endometrioid carcinoma and chemotherapy is usually used for serous endometrial carcinoma. Therefore, the correct classification of subtypes is the key to choosing appropriate adjuvant therapy regimen. At present, the clinical classification of endometrial cancer still refers to Bokhman classification and WHO pathological classification. With the comprehensive promotion of precision medicine and molecular diagnosis and treatment technology, the limitations of traditional endometrial cancer typing methods in the individualized treatment of endometrial cancer, prognosis assessment and related genetic disease screening have become increasingly prominent. An optimized classification method is urgently needed in clinic to provide the exact theoretical and practical basis. In 2013, The Cancer Genome Atlas (TCGA) research center in the United States confirmed the molecular classification of endometrial cancer by integrating genomic features. Compared with Bokhman′s and WHO′s classification, this classification achieved a stronger correlation with the prognosis of patients with endometrial cancer, which opened the curtain for the molecular diagnosis and treatment of endometrial Cancer.

Key words: Endometrial neoplasms, Genome,human, Genes, Mutation, Immunotherapy